- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 417/00 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group
Patent holdings for IPC class C07D 417/00
Total number of patents in this class: 194
10-year publication summary
11
|
5
|
7
|
6
|
5
|
6
|
3
|
6
|
1
|
2
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Bristol-myers Squibb Company | 4881 |
8 |
Novartis AG | 10741 |
7 |
Cytokinetics, Inc. | 279 |
7 |
Merck Sharp & Dohme LLC | 3749 |
6 |
Janssen Pharmaceutica N.V. | 3377 |
5 |
Gilead Sciences, Inc. | 2035 |
3 |
Purdue Pharma L.P. | 501 |
3 |
The University of Hong Kong | 780 |
3 |
Vitro Flat Glass LLC | 466 |
3 |
Theravance Biopharma R&D IP, LLC | 456 |
3 |
LG Chem, Ltd. | 17641 |
2 |
Boehringer Ingelheim International GmbH | 4641 |
2 |
Allergan, Inc. | 2340 |
2 |
Shenzhen China Star Optoelectronics Technology Co., Ltd. | 8476 |
2 |
Life Technologies Corporation | 3311 |
2 |
Vertex Pharmaceuticals Incorporated | 1602 |
2 |
Purdue Research Foundation | 3638 |
2 |
Hutchison MediPharma Enterprises Limited | 14 |
2 |
Klinikum Darmstadt GmbH | 2 |
2 |
Ludwig-Maximilians-Universitat Munchen | 345 |
2 |
Other owners | 126 |